Ruxolitinib cream for vitiligo in children aged 2 to 11
Part of Skin clinical trials.
This trial tests a cream called ruxolitinib to see if it can safely and effectively restore skin color in children with vitiligo. It may help reduce white patches on the skin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 2 and 11 years old.
- Your child must have a type of vitiligo called non-segmental, with white patches covering at least 0.1% of their body but not more than 10%.
- You must be willing to sign a consent form and bring your child to follow-up visits.
- Your child cannot have other skin conditions that cause light or white patches (like tinea versicolor or pityriasis alba).
- Your child cannot have used any treatment that causes skin depigmentation (lightening) before.
- Your child cannot have failed previous treatment with JAK inhibitor medicines (like ruxolitinib) for vitiligo or other inflammatory conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cream called ruxolitinib for adults with vitiligo on the face and neck that has not responded well to another cream (tacrolimus). The goal is to see if this cream can help bring back skin color.
This study tests how well a cream called ruxolitinib works for vitiligo in real-world conditions. It looks at what factors might make the treatment more or less effective.
This trial tests whether adding a type of light therapy (narrow-band UVB) to a daily pill called ritlecitinib works better than the pill alone for treating vitiligo. It may help if you have non-segmental vitiligo covering a moderate amount of skin.
This trial compares two medicines—oral tacrolimus and dexamethasone micro-pulse therapy—in children aged 4 to 12 whose vitiligo is spreading quickly. The goal is to see which treatment works better to stop the spread and help color return to the skin.
This trial tests a new medicine called TEV-53408 to see if it can help with vitiligo, a condition that causes white patches on the skin. It may help by restoring skin color, and the study will check how safe and effective it is.
This study tests whether a cream called ruxolitinib can help children ages 6 to 11 with nonsegmental vitiligo. It aims to see if the cream safely restores color to white patches on the face and body.
Hear when a new Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.